Oncology Vol 31 No 3

COUNTERPOINT: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML

March 15, 2017

As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.